Denali Therapeutics (DNLI) Asset Utilization Ratio (2018 - 2024)
Denali Therapeutics (DNLI) reported Asset Utilization Ratio of 0.0 for Q2 2024, down 99.67% year-over-year from 0.25 in Q3 2023, and down 99.62% on a QoQ basis from 0.22 in Q1 2024.
Denali Therapeutics (DNLI) has 7 years of Asset Utilization Ratio data on file, last reported at 0.0 in Q2 2024.
- Quarterly Asset Utilization Ratio fell 99.67% year-over-year to 0.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was 0.0 (down 99.67% YoY) and the FY2023 annual result came in at 0.25, up 10558.38% from the prior year.
- Asset Utilization Ratio declined to 0.0 in Q2 2024 per DNLI's latest filing, from 0.22 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.28 in Q4 2023 and bottomed at 0.0 in Q2 2024.
- The 5-year median for Asset Utilization Ratio is 0.09 (2022), against an average of 0.13.
- The widest annual swing landed in 2021, when Asset Utilization Ratio jumped 2499.38%; it then sank 99.67% in 2024.
- Tracing DNLI's Asset Utilization Ratio over 5 years: stood at 0.24 in 2020, then sank by 90.48% to 0.02 in 2021, then jumped by 239.29% to 0.08 in 2022, then soared by 254.58% to 0.28 in 2023, then slumped by 99.7% to 0.0 in 2024.
- Per Business Quant, the three latest DNLI Asset Utilization Ratio figures stand at 0.0 (Q2 2024), 0.22 (Q1 2024), and 0.28 (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | 0.22 |
| Dec 31, 2023 | 0.28 |
| Sep 30, 2023 | 0.27 |
| Jun 30, 2023 | 0.25 |
| Mar 31, 2023 | 0.07 |
| Dec 31, 2022 | 0.08 |
| Sep 30, 2022 | 0.09 |
| Jun 30, 2022 | 0.09 |
| Mar 31, 2022 | 0.06 |
| Dec 31, 2021 | 0.02 |
| Sep 30, 2021 | 0.23 |
| Jun 30, 2021 | 0.22 |
| Mar 31, 2021 | 0.20 |
| Dec 31, 2020 | 0.24 |
| Sep 30, 2020 | 0.01 |
| Jun 30, 2020 | 0.02 |
| Mar 31, 2020 | 0.01 |
| Dec 31, 2019 | 0.02 |
| Sep 30, 2019 | 0.21 |
| Jun 30, 2019 | 0.20 |
| Mar 31, 2019 | 0.20 |
| Dec 31, 2018 | 0.21 |
| Sep 30, 2018 | 0.01 |
| Jun 30, 2018 | 0.00 |
| Mar 31, 2018 | 0.00 |